To review the evidence for the efficacy and effectiveness of risperidone in persons with schizophrenia.
Outcomes assessed in the review
The main outcomes assessed were the efficacy of treatment and extrapyramidal, autonomic and central nervous system side-effects. The efficacy of treatment was assessed using the following measures: BPRS, documentation system for the Association for Methodology and Documentation in Psychiatry (AMPD), PANSS, Scale for the Assessment of Negative Symptoms (SANS), Clinical Global Impressions (CGI), Nurses Observation Scale for Inpatient Evaluation (NOSIE-30), Schedule for Affective Disorders and Schizophrenia-Current Version (SADS-C). Side-effects were assessed using the following measures: DVP side-effects rating scale, Extrapyramidal Symptom Rating Scale (ESRSA), Udvalg for Kliniske Undersogelser Side Effect Rating Scale (UKU) and the Abnormal Involuntary Movement Scale (AIMS).
How were decisions on the relevance of primary studies made?
